HER2 Positive Gastric Cancer Market Overview

The global HER2 Positive Gastric Cancer market is estimated to be worth over USD 1779.8 Millionin 2033 and is expected to grow at CAGR of 3.5% during the forecast period (2024-2033). HER2-positive gastric cancer portrays a distinct subtype of gastric or stomach cancer marked by overexpression of the human epidermal growth factor receptor 2 (HER2) protein. This molecular alteration holds an integral role in accelerating aggressive tumour growth and is discovered in approximately 10-20% of gastric cancer cases. The global market for HER2-positive gastric cancer revolves around diagnostic tools and targeted therapies, reflecting advancements in the field of oncology.

Diagnosing HER2 positivity in gastric cancer is crucial for guiding treatment decisions. Similar to HER2-positive breast cancer, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are common diagnostic tests employed to evaluate HER2 status in gastric tumours. Accurate diagnosis supports the identification of patients who is likely to benefit from targeted HER2 therapies, impacting the overall management of gastric cancer.

The market is dominated by targeted therapies such as trastuzumab, which particularly targets HER2-positive cancer cells, impeding their growth. Trastuzumab has illustratedenhanced survival outcomes for patients with HER2-positive gastric cancer, especially when used in combination with chemotherapy. Ongoing research is emphasized on optimizing treatment regimens and exploring additional HER2-targeted agents, such as lapatinib and trastuzumab deruxtecan, to broaden the therapeutic options available.

While the global market for HER2-positive gastric cancer mirrors some trends noticed in HER2-positive breast cancer, it also presents unique challenges. Gastric cancer is often diagnosed at advanced stages, highlighting the prominence of early detection and targeted interventions. Efforts to improve accessibility to diagnostic tools and therapies, specifically in regions with higher prevalence rates, are crucial for addressing global disparities in gastric cancer outcomes.

Therefore, the market for HER2-positive gastric cancer is marked by advancements in diagnostics and targeted therapies, with a focus on improving patient outcomes through early and accurate identification of HER2-positive tumours. The continuing research panorama is accelerating innovation in treatment approaches, offering commitment for improved therapeutic options and improved survival rates for individuals diagnosed with HER2-positive gastric cancer globally.

Figure 1. HER2 Positive Gastric Cancer: Market Size

Get more details on this report - Request Free Sample

Key Market Insights &Current Market Landscape:

The current market landscape of global HER2-positive gastric cancer is characterized by major insights and significant developments. Notable advancements comprise the dominance of targeted therapies such as trastuzumab, which has established itself as a foundation in the treatment of HER2-positive gastric cancer. Substantial product launches, comprising lapatinib and trastuzumab deruxtecan, have diversified the therapeutic armamentarium, offering additional options for patients with HER2-positive gastric cancer and contributing to more personalized treatment approaches.

In terms of diagnostics, immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) continue to be pivotal in identifying HER2 positivity, guiding treatment decisions, and improving the overall management of gastric cancer. The panorama is experiencing a trend towards optimizing treatment regimens through the exploration of combination therapies, with continuing research aimed at enhancingefficiency and overcoming potential resistance issues.

Along with that, the market is impacted by a soaring focus on novel technologies, comprising liquid biopsy techniques. These technologies provide non-invasive methods to monitor disease progression, assess treatment response, and detect minimal residual disease, offering valuable insights for clinicians to tailor treatment strategies dynamically.

Overall, the global market for HER2-positive gastric cancer reflects a dynamic landscape characterized by a combination of established therapies, notable product launches, and the integration of novel technologies. The emphasis on enhancing diagnostic accuracy, optimizing treatment regimens, and exploring innovative therapeutic approaches underscores a commitment to advancing patient care and outcomes in the evolving panorama of HER2-positive gastric cancer treatment.

Market Dynamics

Market Drivers

Soaring Emphasis on the Development of More Effective Treatment Procedures and Advanced Drugs

With an increasing understanding of the molecular complexities underlying HER2-positive gastric cancer, there is an escalated focus on advacned treatment strategies to improve therapeutic outcomes. This focus is fueling the exploration of novel drug formulations and combination therapies, aiming to enhance response rates, extend survival, and mitigate the risk of disease recurrence.

The market is experiencing a rise in research and development efforts dedicated to recognizing and developing advanced drugs particularly tailored for HER2-positive gastric cancer. The advent of new targeted therapies, such as trastuzumab deruxtecan and lapatinib, reflects the promise to expanding the therapeutic arsenal. Also, the focus on combination therapies, incorporating different mechanisms of action, underscores the quest of comprehensive treatment approaches.

This dedication to advancing treatment procedures and drug development not only addresses the clinical needs of patients but also contributes to the overall growth and evolution of the global HER2-positive gastric cancer market. As researchers continue to explore innovative interventions, there is a tangible opportunity to redefine the treatment outlook, providing more effective options and improving the prognosis for individuals diagnosed with HER2-positive gastric cancer.

Market Restraints

With regard to numerous advantages of HER2 Positive Gastric Cancer, the market faces several challenges due to the unique characteristics and requirements associated with them. Some of the key market challenges include:

• Limited Diagnostic Infrastructure: A notable market restraint for HER2-positive gastric cancer is the limited diagnostic infrastructure, specifically in various regions. Inadequate access to advanced diagnostic tools, such as immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH), hinders accurate HER2 status assessment, inhibiting optimal patient stratification and targeted treatment decisions.

Market Opportunities

Increase in Significant Research and Development Investments in Healthcare

The growing commitment to R&D activities, in particular, in oncology, translates into a wealth of resources dedicated to understanding the molecular complexities of HER2-positive gastric cancer. This increased investment nurtures the discovery and development of novel drugs, advancedtreatment modalities, and innovative diagnostic technologies, providing a transformative potential for the field.

With an increasing understanding of the unique challenges posed by HER2-positive gastric cancer, increased R&D investments propel the exploration of targeted therapies and combination treatment approaches. These endeavors not only aim to enhance patient outcomes but also contribute to addressing resistance mechanisms and mitigatingside effects. The opportunity lies not only in the discovery of new therapeutic agents but also in the optimization of existing ones, leading the way for more personalized and effective treatment strategies.

In addition to that, increased R&D investments stimulate collaboration between pharmaceutical companies, research institutions, and academic organizations, fostering a dynamic ecosystem for advancements in HER2-positive gastric cancer management. The synergy between scientific innovation and financial support positions the market on the cusp of breakthroughs, providing hope for enhanced therapeutic options and enhanced prognosis for individuals grappling with HER2-positive gastric cancer across the globe.

Market Trends

• Advancements in Combination Therapies: A significant market trend in the global HER2-positive gastric cancer segment is the growing emphasis on combination therapies. Researchers are exploring synergistic effects by combining HER2-targeted therapies with immunotherapy or other innovative agents. This trend aims to optimize treatment outcomes, overcome potential resistance, and lessen the risk of disease recurrence, reflecting a shift towards more personalized and comprehensive therapeutic approaches.

HER2 Positive Gastric Cancer Market: Key Segments

By Therapy

• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy

By Stage

• Stage I
• Stage II
• Stage III
• Stage IV

By End-User

• Ambulatory surgery Centres
• Hospitals and Specialty clinics
• Others

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

HER2 Positive Gastric Cancer Market: Regional Analysis

North America dominated the market and accounted for the largest revenue share of around 3.4% in 2023. The increasing prevalence of gastric cancer is fueling the growth of the HER2-positive gastric cancer market in North America.Gastric cancer is the third leading cause of cancer mortality with a five-year survival rate of 5% for metastatic disease.Approximately one in five gastric cancers are considered HER2 positive. An estimated 27,600 new cases of gastric cancer will be diagnosed this year and the disease could lead to more than 11,000 deaths in the US in 2020.Thus, the increasing number of gastric cancer cases in the region is expected to rise the demand for effective therapies for treating patients with gastric cancer which in turn is anticipated to fuel the market growth over the forecast period.

Figure 4. HER2 Positive Gastric Cancer Market: Distribution by Region

Get more details on this report - Request Free Sample

Leading HER2 Positive Gastric Cancer Developers

Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape, market size and future opportunities associated with the HER2 Positive Gastric Cancermarket, during the given forecast period. Further, the market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biopharmaceutical industry. Key takeaways of the HER2 Positive Gastric Cancermarket are briefly discussed below. 

The report includes the list of players operating in the global HER2 Positive Gastric Cancermarket. Some of the key players include: 

• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Hutchison Medipharma
• LintonPharm
• Novartis AG
• Ono Pharmaceutical Co. Ltd
• Shanghai Henlius Biotech
• Pfizer
• Sanofi

Recent Developments in the HER2 Positive Gastric Cancer Market

Several recent developments have taken place in the field of HER2 Positive Gastric Cancer, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we’ve outlined in our analysis chronologically.

• In December 2022 - Shanghai Henlius Biotech, Inc. announced that the first patient has been dosed in a phase 1 clinical trial (NCT05394168) of the company’s HLX53, an anti-TIGIT Fc fusion protein, for the treatment of advanced or metastatic solid tumours or lymphomas in China.
• In September 20, 2022 - CytoReason announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs.

Scope of the Report

The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table: